Healthcare Industry News:  Glaucoma 

Devices Ophthalmology

 News Release - September 7, 2006

Coronado Industries to Initiate Direct Sales of Its Pneumatic Trabeculoplasty Treatment into Canadian Market

Initiative Will Allow for Rapid Introduction of the Glaucoma Treatment in a Major Marketplace

FOUNTAIN HILLS, Ariz.--(HSMN NewsFeed)--Sept. 7, 2006--Ophthalmic International (, a wholly owned subsidiary of Coronado Industries (OTCBB: CNDO; announced today the company will initiate direct marketing of its Pneumatic Trabeculoplasty (PNT) product in the Canadian market. This decision follows the granting of a Medical Device License by Health Canada in late June 2006.

In making the announcement today, Richard Smith, chairman and CEO of Coronado Industries, said the decision by the board of directors to approve the direct launch of the product in Canada represented a thoroughly new approach for the company. "Outside of North America, we have until now utilized a sales, distribution and marketing approach which has involved select medical device distributors. Our decision to directly market and distribute our products in Canada marks the beginning of a new, and potentially more profitable, chapter in our company's history," he said.

Dr. John W. Sharkey, president of Ophthalmic International, said the company has been working over the last 60 days preparing the marketing materials required to launch the product in Canada. "One of the main drivers for our decision to directly market the product in Canada was the realization that we had been presented with a unique opportunity to capture a greater portion of a valuable product franchise. Given the close proximity of key Canadian population centers, we believe that our plans offer the potential to generate near term revenue for the company.

Dr. Sharkey said over the next few weeks the company will be targeting eye care professionals in order to make them aware of the availability of PNT in Canada. The plan also involves a strong tie-in with this year's American Academy of Ophthalmology (AAO) meeting in Las Vegas since many Canadian eye care professionals will be attending this meeting and will have the opportunity to meet with doctors from Europe who are successfully performing the procedure.

Smith said that he and the Coronado team looked forward, with great satisfaction, to the upcoming launch adding that an additional benefit arising out of the introduction of PNT in Canada is that it will allow some of North Americas' most prominent Key Opinion Leaders (KOLs) who are based in Canada to gain firsthand experience with the technique and the benefits it offers. "Having KOLs in both Europe and North America can only help in our global roll out of PNT," he said.

Ophthalmic International, is focused on the development and commercialization of its patented procedure as a cost-effective alternative for the treatment of the most common types of Glaucoma, which are open angle and pigmentary, as well as for the treatment of ocular hypertension.

For more information about Coronado Industries, please visit our Web site at

Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the company's products, increased levels of competition for the company, new products and technological changes, the company's dependence on third-party suppliers, and other risks detailed from time to time in the company's periodic reports filed with the Securities and Exchange Commission.

Source: Coronado Industries

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.